Transcatheter Cardiovascular Therapeutics (TCT)

The Transcatheter Cardiovascular Therapeutics (TCT) conference is the Cardiovascular Research Foundation's (CRF) annual scientific symposium and the largest conference focused on interventional cardiovascular medicine. TCT includes seminars on all areas of intervention cardiology, structural heart, vascular in interventions, peripheral artery disease, and other procedures in the cath lab.

Gilbert H. Tang, MD, professor in the Department of Cardiovascular Surgery at the Icahn School of Medicine and surgical director of the Structural Heart Program at the Mount Sinai Health System, explains how to overcome the limited imaging windows of the tricupid valve using a TEE and intracardiac echo (ICE) at TCT 2024.

How to overcome imaging challenges during tricuspid valve procedures

Gilbert Tang, MD, surgical director of the structural heart program at the Mount Sinai Health System, discussed a key challenge care teams often encounter during tricuspid valve procedures. 

Deepak Bhatt, MD, MPH, MBA, director of the Mount Sinai Fuster Heart Hospital, explains the research and therapies in development to treat coronary inflammation. In 2023, the FDA cleared the use colchicine and since there has been an explosion of interest in this area. #TCT #TCT24 #TCT2024 #AHA24

Cardiologist examines the latest breakthroughs in coronary inflammation research

Deepak Bhatt, MD, MPH, MBA, spoke to Cardiovascular Business about the growing importance of evaluating coronary inflammation in heart patients. There has been an explosion of interest in this area since the FDA's 2023 clearance of colchicine.

Video interview with J.D. Corl, MD, explaining the use of the new E8 and Javelin Shockwave IVL catheters in PAD.

New balloonless IVL catheter offers an alternative to atherectomy in tight lesions, CTOs

J.D. Corl, MD, shared his experience using two new IVL catheters from Shockwave Medical to treat patients with heavily calcified peripheral arteries. He considers both new devices a significant upgrade. 

Philippe Genereux explains how EARLY TAVR will help raise awareness for undertreatment of TAVR.

New data put a spotlight on troubling TAVR trends

Philippe Genereux, MD, principal investigator of the EARLY TAVR trial, noted that many patients with severe AS still go untreated.

Gilbert Tang, MD, explains new tricuspid TEER TRILUMINATE data that now shows clinical efficacy.

Tricuspid TEER shows clinical efficacy for first time in newest TRILUMINATE data

Gilbert Tang, MD, spoke to Cardiovascular Business about late-breaking data from the TRILUMINATE IDE trial. While early results were promising, these latest findings highlight the TriClip device's true value for the first time.

Abbott TriClip tricuspid edge-to-edge repair (T-TEER) device shown on transesophageal echo (TEE). The device clips together the leaflets of the valve to form a better seal and reduce regurgitation without the need for open heart surgery. Photo by Dave Fornell

Cardiology societies push Medicare to pay for tricuspid TEER

Six multispecialty cardiovascular societies have called on CMS to approve Medicare payments for tricuspid transcatheter edge-to-edge repair (T-TEER).

Video of FDA Commissioner Robert Califf, MD, explaining the need for clinicians to take up fight against health misinformation with grassroots efforts in their communities. #misinformation #FDA #science

FDA commissioner urges clinicians to join fight against medical misinformation

FDA Commissioner Robert Califf, MD, said the clinical community needs to combat health misinformation at a grassroots level. He warned that patients are immersed in a "sea of misinformation without a compass."

Sanjit Jolly, MD, says cholchicine failed to help heart attack patients in the CLEAR SYNERGY (OASIS 9) presented as a TCT 2024 late-breaker.

Cardiologist explores why colchicine failed to help heart attack patients

Sanjit S. Jolly, MD, MSc, reviewed his team's late-breaking data on treating heart attack patients with colchicine. "I think inflammation is an important area, but I don't think colchicine is the magic bullet," he said.